BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review

Published: May 2013

Publisher: GlobalData

Product ref: 172200

Pages: 38

Format: PDF

Delivery: Immediate download

Email details: Forward this to a colleague

Satisfaction guarantee: Yes - details here

Price guarantee: Yes - details here

Price: $ 125.00

Report description

BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights:

BioGaia AB (BioGaia) is a biotechnology company, conducts the development, marketing and sale of probiotic products and solutions. Also, the company licenses its products principally to functional foods, beverages, and healthcare sectors. The company operates under three reportable business segments, namely; Finished consumer products include tablets, drops, straws, caps and oral health products; Component products include infant cereal products; and other products offers Animal health care products. BioGaia's products are based on various strains of lactic acid bacterium, Lactobacillus reuteri.

BioGaia AB Key Recent Developments:

Apr 26, 2013: BioGaia Reports Revenue Of SEK78.1m In Q1 2013
Feb 08, 2013: BioGaia Reports Revenue Of SEK72.4m In Q4 2012
Dec 17, 2012: BioGaia Signs Two New Distribution Agreements With Pharmaforte And Dexcel Pharma
Oct 23, 2012: BioGaia Reports Revenue Of SEK62.8m In Q3 2012
Oct 15, 2012: BioGaia's Probiotics Demonstrate Safety And Efficacy In Premature Infants With Necrotizing Enterocolitis

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.

Table of contents

Section 1 - About the Company
BioGaia AB - Key Facts
BioGaia AB - Key Employees
BioGaia AB - Key Employee Biographies
BioGaia AB - Major Products and Services
BioGaia AB - History
BioGaia AB - Company Statement
BioGaia AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
BioGaia AB - Business Description
BioGaia AB - SWOT Analysis
SWOT Analysis - Overview
BioGaia AB - Strengths
Strength - Strong Profitability
Strength - Strong Distribution Network Through Agreements
Strength - Strong Liquidity
BioGaia AB - Weaknesses
Weakness - Dependent on European Market
BioGaia AB - Opportunities
Opportunity - Emerging Markets
Opportunity - Spate of New Product Launches
Opportunity - Changing Demographics
BioGaia AB - Threats
Threat - Growing Parallel Trade
Threat - Uncertain R&D Outcomes
Threat - Unclear EFSA requirements
BioGaia AB - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
BioGaia AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
BioGaia AB, Recent Developments
Apr 26, 2013: BioGaia Reports Revenue Of SEK78.1m In Q1 2013
Feb 08, 2013: BioGaia Reports Revenue Of SEK72.4m In Q4 2012
Dec 17, 2012: BioGaia Signs Two New Distribution Agreements With Pharmaforte And Dexcel Pharma
Oct 23, 2012: BioGaia Reports Revenue Of SEK62.8m In Q3 2012
Oct 15, 2012: BioGaia's Probiotics Demonstrate Safety And Efficacy In Premature Infants With Necrotizing Enterocolitis
Sep 17, 2012: BioGaia's Probiotic Found To Be Effective Against Colic In Infants
Sep 07, 2012: BioGaia’s Probiotic Prevents Necrotizing Enterocolitis In High Risk Premature Infants
Aug 21, 2012: BioGaia Reports Revenue Of SEK75.7m In Q2 2012
May 14, 2012: BioGaia Initiates Investigative Study In Type 2 Diabetics
May 08, 2012: BioGaia Reports Revenue Of SEK78.3m In Q1 2012
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables

BioGaia AB, Key Facts
BioGaia AB, Key Employees
BioGaia AB, Key Employee Biographies
BioGaia AB, Major Products and Services
BioGaia AB, History
BioGaia AB, Other Locations
BioGaia AB, Subsidiaries
BioGaia AB, Key Competitors
BioGaia AB, Ratios based on current share price
BioGaia AB, Annual Ratios
BioGaia AB, Interim Ratios
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
BioGaia AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

BioGaia AB, Performance Chart (2008 - 2012)
BioGaia AB, Ratio Charts
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 26,

Price: $ 125.00

Related research categories

By company: SWOT analysis